This comprehensive session delves into the spectrum of heart failure management, from acute presentations to chronic conditions. Key topics include the cardio-hepatic syndrome and right ventricular dysfunction in HFmrEF, prognostic implications of heart failure etiologies, and innovative approaches such as AI-assisted echocardiography for early detection of...

This session addresses strategies to optimize outcomes in coronary bifurcation PCI. It evaluates the impact of cutting and scoring balloons versus non-compliant balloons on stent expansion, predictors of target vessel revascularization using the POKI technique, and compares stent and non-stent approaches in side branch myocardial infarction...

This session provides an in-depth review of contemporary management of aortic stenosis, covering diagnostic advancements, temporal trends, and treatment outcomes. It includes insights from the LAPLACE-TAVI registry focusing on low-risk patients, discusses the growing feasibility of day-case TAVI procedures, compares transcatheter and surgical valve replacements in...

This session examines both established knowledge and novel advances in left main PCI. Topics include the use of novel stents and laser atherectomy in calcified lesions, the prognostic impact of cardiac motion during bifurcation PCI, effects of left ventricular dysfunction, and sex-specific survival outcomes, as well...

Explore the global challenge of hypertension, affecting one in three adults, and the strategies for screening, diagnosis, and management, including lifestyle modifications, pharmacotherapy, and device-based treatments, as outlined by Sofie Brouwers.

Jonathan Curio provides his take on TRISCEND II trial results presented by Vinod H. Thourani at ACC.26 in New Orleans.

Martin Bergmann reviews the evolving evidence for LAAC, examining how recent landmark trials such as OPTION, CLOSURE‑AF and CHAMPION‑AF are reshaping patient selection and expanding the role of LAAC across a broader spectrum of patients with atrial fibrillation.

Nicola Ryan provides her take on the BRIGHT-4 study, which was presented during AHA 2022 in Chicago, & simultaneously published in the Lancet.

This study was a randomised control trial designed to assess if bivalirudin plus a high dose infusion for 2-4 hours post PPCI was superior to unfractionated...

In this article, Jens Erik Nielsen-Kudsk reviews the evolution of left atrial appendage closure, from early trials such as PROTECT‑AF to recent evidence including CHAMPION‑AF, and discusses its expanding role in stroke prevention for atrial fibrillation.

In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.

Authored by Hector Garcia-Garcia and Jorge Sanz-Sanchez, this article examines pivotal randomized clinical trials on drug-coated balloons in coronary artery disease. It highlights their role in managing in-stent restenosis, de novo small vessel lesions, and large vessel lesions while exploring future directions through ongoing trials.

Daniele Giacoppo reports and provides his perspective on the main results of the ambitious NEOMINDSET trial, presented by Pedro Lemos from the Hospital Israelita Albert Einstein, São Paulo, Brazil, during a Late Breaking Trials session at the ESC Congress 2025 in Madrid, and simultaneously published in the New...